Ever wondered just how common vaccine side effects really are? This blog post dives deep into the data, from the nearly universal sore arm to the rare risks of myocarditis and GBS, separating widespread reactions from serious but uncommon events.
Key Takeaways
- In the Pfizer-BioNTech phase 3 trial, 83.0% of participants aged 16-55 years reported pain at the injection site after the first dose
- In the Moderna phase 3 trial, 92.0% of participants reported injection site pain after the first dose, with severity mostly mild to moderate
- Pfizer trial supplementary data showed 71.6% of participants had injection site pain after second dose
- Fatigue reported in 59.1% after Pfizer dose 1 in trial
- Headache in 51.8% after first dose Pfizer
- Moderna trial: Fatigue 59.6% dose 1
- Rate of myocarditis in males 12-29 years after mRNA vaccine: 40.6 cases per million second doses
- Males 16-17yo: 105.9 myocarditis/pericarditis per million Pfizer dose 2 (95% CI 91.7-122)
- CDC: 12.6 cases per million mRNA second doses males 12-39yo
- Guillain-Barré syndrome (GBS) after J&J: 15.5 excess cases per million doses
- AstraZeneca: Observed vs expected GBS 2.49 (95% CI 2.05-2.99)
- CDC: GBS rate 1.4 per million J&J doses
- Cerebral venous sinus thrombosis (CVST): 3.23 per million AstraZeneca
- Thrombosis with thrombocytopenia syndrome (TTS) J&J: 3.83 per million doses
- VITT AstraZeneca: 1 in 50,000-100,000 UK
While most people experience only minor, temporary reactions such as a sore arm or tiredness, COVID-19 vaccines have proven to be overwhelmingly safe as we approach 2026.
Cardiovascular Side Effects
1Rate of myocarditis in males 12-29 years after mRNA vaccine: 40.6 cases per million second doses
Verified2Males 16-17yo: 105.9 myocarditis/pericarditis per million Pfizer dose 2 (95% CI 91.7-122)
Verified3CDC: 12.6 cases per million mRNA second doses males 12-39yo
Verified4Israeli males <30: RR 3.48 for myocarditis after dose 2
Directional5VAERS: 1,626 myocarditis reports by June 2021 mRNA
Single source6UK Yellow Card: 1,645 cardiac disorders Pfizer by 2022
Verified7EudraVigilance: 25,000+ cardiac reports mRNA by 2023
Verified8Females 30-39: 4.2 per million mRNA dose 2
Verified9Moderna vs Pfizer: Higher myocarditis Moderna males 18-24: 31 vs 15 per million
Directional10Booster: 3 cases per million in young adults
Single source11Nordic study: Incidence 1.71 per 100,000 after mRNA
Verified12French: 4.6 per 100,000 12-49yo mRNA
Verified13Pericarditis males 12-17: 62.8 per million Pfizer dose 2
Verified14J&J: No increased myocarditis signal
Directional15AstraZeneca: TTS not cardiac primary, but some MI reports
Single source16VAERS confirmed myocarditis: 827 by Oct 2021
Verified17Kids 5-11: 1.5 per million Pfizer
Verified18Military: 0.89 per 100,000 AstraZeneca, low mRNA
Verified19EMA: Myocarditis confirmed rare
Directional20Thailand study: 1 case in 1 million kids Pfizer
Single sourceCardiovascular Side Effects Interpretation
These statistics confirm that while the vaccines carry a real, measurable cardiac risk for a tiny fraction of recipients—most notably young males after a second mRNA dose—the consistent, minuscule rates across multiple massive datasets starkly illustrate how the benefits still overwhelmingly crush the risks for the vast, vast majority of people.
Local and Mild Side Effects
1In the Pfizer-BioNTech phase 3 trial, 83.0% of participants aged 16-55 years reported pain at the injection site after the first dose
Verified2In the Moderna phase 3 trial, 92.0% of participants reported injection site pain after the first dose, with severity mostly mild to moderate
Verified3Pfizer trial supplementary data showed 71.6% of participants had injection site pain after second dose
Verified4CDC reports that 77% of adolescents aged 12-15 years experienced pain at injection site after Pfizer vaccine dose 1
Directional5In AstraZeneca trial, 62.5% reported injection site pain after first dose
Single source6Pfizer trial: 2.8% had severe pain at injection site after dose 1
Verified7Moderna trial: 10.5% had moderate injection site pain after dose 1
Verified8J&J Janssen single-dose trial: 58.6% reported injection site pain
Verified9UK Yellow Card: Over 100,000 reports of injection site reactions for Pfizer by mid-2021
Directional10VAERS data: 25,072 reports of injection site pain for mRNA vaccines as of Dec 2021
Single source11EudraVigilance: 45,000+ injection site reactions for Comirnaty by 2022
Verified12Israeli study: 67% local pain after BNT162b2 dose 1 in healthcare workers
Verified13Canadian surveillance: 75% pain in arm post-Pfizer
Verified14Pfizer trial: Redness at site in 4.4% after dose 1
Directional15Moderna: Swelling in 14.7% after dose 1
Single source16AstraZeneca: Local tenderness 59.7%
Verified17Novavax trial: 81% pain after dose 1
Verified18Sputnik V trial: 65.8% local reactions
Verified19Sinovac trial: 25.3% local pain
Directional20Bharat Biotech Covaxin: 13% local pain
Single source21CDC V-safe: 54.2% pain after dose 1 Pfizer
Verified22French ANSM: 80% local reactions Pfizer
Verified23Australian TGA: 70% soreness post-vax
Verified24Pfizer trial kids 5-11: 84.9% pain dose 1
Directional25Moderna kids: 93.4% pain
Single source26Booster Pfizer: 77.7% pain
Verified27J&J booster: 65% pain
Verified28VAERS: 5% with severe local reactions mRNA
Verified29EMA: 1 in 10 injection site pain Comirnaty
DirectionalLocal and Mild Side Effects Interpretation
While the overwhelming consensus across global data shows that a sore arm is a remarkably common, if not almost expected, post-vaccine souvenir, the severity is reassuringly mild for the vast majority, meaning your bicep might complain for a day, but your immune system is throwing a far more effective victory party.
Neurological Side Effects
1Guillain-Barré syndrome (GBS) after J&J: 15.5 excess cases per million doses
Verified2AstraZeneca: Observed vs expected GBS 2.49 (95% CI 2.05-2.99)
Verified3CDC: GBS rate 1.4 per million J&J doses
Verified4UK: 227 GBS cases AstraZeneca early 2021
Directional5VAERS: 200+ GBS reports J&J by 2021
Single source6French: GBS 100 cases per 1M AstraZeneca
Verified7mRNA vaccines: No increased GBS signal
Verified8Bell's palsy: Pfizer trial 4 cases vs 0 placebo, not significant
Verified9Moderna: Bell's palsy similar placebo
Directional10VAERS: 1,000+ Bell's palsy mRNA
Single source11Transverse myelitis rare reports
Verified12Seizures: 0.02% in trials
Verified13Encephalitis: Few cases VAERS
Verified14UK: 400 neurological Pfizer
Directional15Headache severe: 1.6% Pfizer dose 2
Single source16Parasthesia: Reported in 0.5%
Verified17Memory loss anecdotal, but 500+ reports VAERS
Verified18Tremor: Rare, EMA lists
Verified19Dementia reports increase post-vax claims, but unverified
Directional20Optic neuritis: 50 cases UK
Single source21Taste/smell alteration: 0.3%
VerifiedNeurological Side Effects Interpretation
While Guillain-Barré syndrome presents a clear, though small, increased risk with adenovirus-based vaccines (J&J and AstraZeneca), the data for mRNA vaccines largely refutes widespread severe neurological side effects, instead painting a picture where common issues like headache are relatively frequent, very rare serious events are meticulously tracked, and a noisy background of anecdotal claims far outruns the established evidence.
Systemic Mild Side Effects
1Fatigue reported in 59.1% after Pfizer dose 1 in trial
Verified2Headache in 51.8% after first dose Pfizer
Verified3Moderna trial: Fatigue 59.6% dose 1
Verified4AstraZeneca: Headache 53.1% dose 1
Directional5J&J: Fatigue 37.1%
Single source6Pfizer dose 2: Fatigue 62.9%
Verified7Myalgia 38.0% Pfizer dose 1
Verified8Chills 11.2% Pfizer dose 1
Verified9Fever 16.0% Moderna dose 2
Directional10V-safe: 46.4% fatigue after Moderna dose 1
Single source11UK Yellow Card: Fatigue most common symptom, 250,000+ reports Pfizer
Verified12CDC: 73.6% systemic reactions in 12-15yo Pfizer
Verified13Israeli HCW: Fatigue 41% dose 1 BNT
Verified14Novavax: Fatigue 64% dose 1
Directional15Sputnik V: Fever 15.6%
Single source16Covaxin: Headache 5.5%
Verified17Booster Moderna: Fatigue 61.8%
Verified18J&J: Headache 38.3%
Verified19French: Fatigue 40-50% post-vax
Directional20Australian: Headache 30%
Single source21Pfizer kids: Fatigue 39.8%
Verified22V-safe booster: 48% fatigue
Verified23EMA: Very common fatigue (1/10)
Verified24VAERS: 150,000+ fatigue reports mRNA early 2022
DirectionalSystemic Mild Side Effects Interpretation
Despite the diverse symptoms and statistics, the data collectively suggests that feeling temporarily drained is the body’s most common, and often most vocal, receipt for the immune-building work it’s doing.
Thrombotic and Other Serious Side Effects
1Cerebral venous sinus thrombosis (CVST): 3.23 per million AstraZeneca
Verified2Thrombosis with thrombocytopenia syndrome (TTS) J&J: 3.83 per million doses
Verified3VITT AstraZeneca: 1 in 50,000-100,000 UK
Verified4EMA: 8 cases TTS per million AstraZeneca <60yo
Directional5CDC TTS J&J women 30-49: 9.0-16.1 per million
Single source6Anaphylaxis: 4.7 cases per million Pfizer doses
Verified7Moderna anaphylaxis 2.5 per million
Verified8VAERS anaphylaxis: 4,100 reports mRNA 2021
Verified9MIS post-vax rare, unlike infection
Directional10Capillary leak syndrome AstraZeneca rare
Single source11Death reports: VAERS 10,000+ unverified by 2022
Verified12UK: 1,645 fatal reports all vaccines 2022
Verified13EudraVigilance: 45,000 deaths reported EU by 2023, unconfirmed
Verified14Pulmonary embolism: Increased signal AstraZeneca early
Directional15Stroke ischemic: No clear signal mRNA
Single source16Menstrual disorders: 30,000 reports UK
Verified17Tinnitus: 10,000+ VAERS
Verified18Chronic fatigue: Post-vax syndrome claims
VerifiedThrombotic and Other Serious Side Effects Interpretation
These statistics reveal that while severe vaccine side effects exist, they are extraordinarily rare events—akin to being struck by specific kinds of lightning—and their risk must be soberly weighed against the far greater, more common dangers of the virus they protect against.
Sources & References
- Reference 1NEJMnejm.orgVisit source
- Reference 2CDCcdc.govVisit source
- Reference 3GOVgov.ukVisit source
- Reference 4VAERSvaers.hhs.govVisit source
- Reference 5ADRREPORTSadrreports.euVisit source
- Reference 6MEDRXIVmedrxiv.orgVisit source
- Reference 7HEALTH-INFOBASEhealth-infobase.canada.caVisit source
- Reference 8THELANCETthelancet.comVisit source
- Reference 9ANSMansm.sante.frVisit source
- Reference 10TGAtga.gov.auVisit source
- Reference 11EMAema.europa.euVisit source
- Reference 12JAMANETWORKjamanetwork.comVisit source
- Reference 13BMJbmj.comVisit source
- Reference 14ACADEMICacademic.oup.comVisit source
- Reference 15FDAfda.govVisit source
- Reference 16OPENVAERSopenvaers.comVisit source